|
DGAP-News: SynBiotic SE
/ Key word(s): Capital Increase
Munich, October 27, 2021. The cannabis company SynBiotic SE has successfully completed another capital increase. 334,000 new shares were placed with institutional investors at an issue price of EUR 21 per share. With the proceeds of around 7 million Euros, the listed company intends to finance further growth and expansion. A large part of the proceeds from the issue - possibly in tandem with targeted use of the company's own shares - is to be dedicated to strategic acquisitions. SynBiotic SE is the first listed specialist cannabis company in Germany. Since its initial listing in November 2019, it has raised more than 13 million Euros and invested early in the pan-European expansion of business, new products and more intensive marketing. CEO Lars Müller says: "A look at the outgoing year shows that we have set a breath-taking pace with the growth of SynBiotic SE. The new government in Germany is now giving us additional tailwind. The details are not yet known, but we expect a significant step forward in terms of legalization and commercialization. As the market leader in Germany, we are ideally positioned to transform this tailwind into expanding market shares and increasing sales. At the same time, we want to accelerate growth in other European countries and establish ourselves as the European market leader." About SynBiotic SE SynBiotic SE is the first German listed cannabis company to pursue an EU-focused buy-and-build investment approach. The core business of the platform company is the research and development of new cannabinoid and terpene-based solutions to major social problems such as pain, sleep-disorders and anxiety. In addition, the platform deals with the production of various cannabinoids and develops and distributes pharmaceutical and dietary supplements as well as cosmetic products under its own brands.
27.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | SynBiotic SE |
| Barer Str. 7 | |
| 80333 München | |
| Germany | |
| E-mail: | office@synbiotic.com |
| Internet: | https://www.synbiotic.com/ |
| ISIN: | DE000A3E5A59 |
| WKN: | A3E5A5 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange |
| EQS News ID: | 1243857 |
| End of News | DGAP News Service |
|
|
1243857 27.10.2021
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
